Stem Cell-derived Extracellular Vesicles: A Promising Nano Delivery Platform to the Brain?

Guo, Yuying; Hu, Dongsheng; Lian, Lu; Zhao, Linna; Li, Mingli; Bao, Hongduo; Xu, Shixin

doi:10.1007/s12015-022-10455-4

Cited by 9 publications

(7 citation statements)

References 238 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[156][157][158] This demonstrates that EVs administered intranasally can be efficiently delivered to the brain in rodent models. Once various challenges are circumvented, 159,160 naı ¨ve or drug-loaded IN-EVs could potentially be used to transport therapeutic agents for the treatment of neurological diseases in humans (Table 2).…”

Section: Alternative Non-invasive Delivery Via Nose-to-brain Deliverymentioning

confidence: 99%

Enhancing paracellular and transcellular permeability using nanotechnological approaches for the treatment of brain and retinal diseases

Khalil,

Barras,

Boukherroub

et al. 2024

Nanoscale Horiz.

View full text Add to dashboard Cite

show abstract

Section: Alternative Non-invasive Delivery Via Nose-to-brain Deliverymentioning

confidence: 99%

Enhancing paracellular and transcellular permeability using nanotechnological approaches for the treatment of brain and retinal diseases

Khalil,

Barras,

Boukherroub

et al. 2024

Nanoscale Horiz.

View full text Add to dashboard Cite

show abstract

“…These cells possess inherent tropism for GBM and can be genetically modified or loaded with NPs to enhance their therapeutic efficacy. 75 …”

Section: Conclusion and Future Perspectivementioning

confidence: 99%

Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier

Lim,

Yee,

Khang

2024

IJN

View full text Add to dashboard Cite

The blood-brain barrier (BBB) and blood-tumor barrier (BTB) pose substantial challenges to efficacious drug delivery for glioblastoma multiforme (GBM), a primary brain tumor with poor prognosis. Nanoparticle-based combinational strategies have emerged as promising modalities to overcome these barriers and enhance drug penetration into the brain parenchyma. This review discusses various nanoparticle-based combinatorial approaches that combine nanoparticles with cell-based drug delivery, viral drug delivery, focused ultrasound, magnetic field, and intranasal drug delivery to enhance drug permeability across the BBB and BTB. Cell-based drug delivery involves using engineered cells as carriers for nanoparticles, taking advantage of their intrinsic migratory and homing capabilities to facilitate the transport of therapeutic payloads across BBB and BTB. Viral drug delivery uses engineered viral vectors to deliver therapeutic genes or payloads to specific cells within the GBM microenvironment. Focused ultrasound, coupled with microbubbles or nanoparticles, can temporarily disrupt the BBB to increase drug permeability. Magnetic field-guided drug delivery exploits magnetic nanoparticles to facilitate targeted drug delivery under an external magnetic field. Intranasal drug delivery offers a minimally invasive avenue to bypass the BBB and deliver therapeutic agents directly to the brain via olfactory and trigeminal pathways. By combining these strategies, synergistic effects can enhance drug delivery efficiency, improve therapeutic efficacy, and reduce off-target effects. Future research should focus on optimizing nanoparticle design, exploring new combination strategies, and advancing preclinical and clinical investigations to promote the translation of nanoparticle-based combination therapies for GBM.

show abstract

“…The biggest advantage of EVs as drug delivery vehicles is probably that EVs can be taken from an organism and returned to the same organism in vivo after being loaded with therapeutic agents, which are thought to be non-immunogenic [ 66 ]. Another advantage is that EVs can carry molecules through physiological barriers, such as the blood–brain barrier, which are hard to cross using conventional delivery methods; this is particularly true when using nucleic acids as cargo [ 67 , 68 , 69 ]. When exogenous RNAs are directly introduced into the body, they are normally degraded by nucleases or filtered in the kidneys before reaching the target site.…”

Section: Extracellular Vesicles: An Overview Of Their Origin and Comp...mentioning

confidence: 99%

Extracellular Vesicles as New Players in Drug Delivery: A Focus on Red Blood Cells-Derived EVs

et al. 2023

View full text Add to dashboard Cite

The article is divided into several sections, focusing on extracellular vesicles’ (EVs) nature, features, commonly employed methodologies and strategies for their isolation/preparation, and their characterization/visualization. This work aims to give an overview of advances in EVs’ extensive nanomedical-drug delivery applications. Furthermore, considerations for EVs translation to clinical application are summarized here, before focusing the review on a special kind of extracellular vesicles, the ones derived from red blood cells (RBCEVs). Generally, employing EVs as drug carriers means managing entities with advantageous properties over synthetic vehicles or nanoparticles. Besides the fact that certain EVs also reveal intrinsic therapeutic characteristics, in regenerative medicine, EVs nanosize, lipidomic and proteomic profiles enable them to pass biologic barriers and display cell/tissue tropisms; indeed, EVs engineering can further optimize their organ targeting. In the second part of the review, we focus our attention on RBCEVs. First, we describe the biogenesis and composition of those naturally produced by red blood cells (RBCs) under physiological and pathological conditions. Afterwards, we discuss the current procedures to isolate and/or produce RBCEVs in the lab and to load a specific cargo for therapeutic exploitation. Finally, we disclose the most recent applications of RBCEVs at the in vitro and preclinical research level and their potential industrial exploitation. In conclusion, RBCEVs can be, in the near future, a very promising and versatile platform for several clinical applications and pharmaceutical exploitations.

show abstract

Stem Cell-derived Extracellular Vesicles: A Promising Nano Delivery Platform to the Brain?

Cited by 9 publications

References 238 publications

Enhancing paracellular and transcellular permeability using nanotechnological approaches for the treatment of brain and retinal diseases

Enhancing paracellular and transcellular permeability using nanotechnological approaches for the treatment of brain and retinal diseases

Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier

Extracellular Vesicles as New Players in Drug Delivery: A Focus on Red Blood Cells-Derived EVs

Contact Info

Product

Resources

About